Alamar Biosciences (NASDAQ:ALMR) Reaches New 12-Month High After Earnings Beat

Key Points

• Alamar Biosciences beat quarterly expectations: The company reported a $0.22 per-share adjusted loss versus analysts’ expected $0.36 loss, with revenue of $29.43 million, up 82% year over year.
• Shares reached a new 52-week high of $32.15 after the earnings release. Analysts maintain a “Moderate Buy” consensus, with an average price target of $31.80 and several targets raised to $35.
• Management issued optimistic 2026 guidance of $116 million–$120 million in revenue and plans to place more than 100 instruments, though the company remains unprofitable and investors are watching margin and cash-flow improvement.

Alamar Biosciences, Inc. (NASDAQ:ALMR - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday following a stronger than expected earnings report. The stock traded as high as $32.15 and last traded at $31.94, with a volume of 75588 shares. The stock had previously closed at $27.99.

The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.14. The company had revenue of $29.43 million during the quarter.

Key Stories Impacting Alamar Biosciences

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Alamar reported second-quarter revenue of $29.43 million, while its adjusted loss of $0.22 per share was better than the analyst consensus loss of $0.36. The earnings beat suggests improving operating execution. Alamar Q2 earnings report
• Positive Sentiment: Management issued 2026 revenue guidance of $116 million to $120 million, above the roughly $113.1 million analyst estimate. The company also outlined plans to place more than 100 instruments and generate over $400,000 in annual pull-through revenue per instrument, indicating confidence in demand for its platform. Alamar 2026 revenue outlook
• Positive Sentiment: Second-quarter revenue reportedly increased 82% year over year, highlighting rapid commercial expansion. Management’s earnings-call commentary also emphasized accelerating instrument adoption and recurring consumables revenue. Alamar Q2 earnings call highlights
• Positive Sentiment: Alamar expanded its global partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures. The collaboration could broaden the use of Alamar’s proteomics technology in Alzheimer’s research and improve the company’s visibility with pharmaceutical and research customers. Alamar global partnership
• Negative Sentiment: Despite the earnings beat and strong growth, Alamar remains unprofitable. The quarterly loss and the absence of a specific profitability target leave investors focused on how quickly revenue growth can translate into improving margins and cash flow.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Wall Street Zen raised Alamar Biosciences to a "hold" rating in a report on Saturday, April 25th. Leerink Partners started coverage on shares of Alamar Biosciences in a report on Tuesday, May 12th. They issued an "outperform" rating and a $35.00 target price on the stock. Stifel Nicolaus set a $32.00 target price on shares of Alamar Biosciences in a research report on Tuesday. JPMorgan Chase & Co. lifted their price target on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an "overweight" rating in a report on Tuesday. Finally, Bank of America started coverage on shares of Alamar Biosciences in a research report on Tuesday, May 12th. They issued a "neutral" rating and a $27.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $31.80.

Alamar Biosciences Stock Performance

The company has a market capitalization of $2.30 billion and a PE ratio of -19.11. The business has a fifty day moving average price of $24.58.

Alamar Biosciences Company Profile

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source